As Amgen waits for an FDA decision on a second indication for its B cell-depleting therapy Uplizna, it has new data suggesting a third may be coming down the pipe. New data from the phase 3 MINT trial ...

It’s been a lovely week here at TSA, and as we’ve counted down our most-wanted games through the start of the year, we’ve been playing a bunch of things in the here and now. I’ve been having a great ...

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from a phase 3 trial of gefurulimab, a once-weekly self-administered treatment ...

Neuromuscular disorders affect nerves that control voluntary muscles, including those in your arms, legs, and face. Nerve damage can lead to muscle weakness and loss of control. Examples of ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.